<code id='88A656321D'></code><style id='88A656321D'></style>
      • <acronym id='88A656321D'></acronym>
      <center id='88A656321D'><center id='88A656321D'><tfoot id='88A656321D'></tfoot></center><abbr id='88A656321D'><dir id='88A656321D'><tfoot id='88A656321D'></tfoot><noframes id='88A656321D'>
      • <optgroup id='88A656321D'><strike id='88A656321D'><sup id='88A656321D'></sup></strike><code id='88A656321D'></code></optgroup>
        5. <b id='88A656321D'><label id='88A656321D'><select id='88A656321D'><dt id='88A656321D'><span id='88A656321D'></span></dt></select></label></b><u id='88A656321D'></u>
          <i id='88A656321D'><strike id='88A656321D'><tt id='88A656321D'><pre id='88A656321D'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-09-28 02:35:12 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：7343
                                  
                                    
          
                                   
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP
          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.
          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.
          advertisement
          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          One Duchenne patient's bittersweet hope for new treatment
                                
                            
          Next article：  
                                      
                                          Hepatitis C has a cure — but many Americans still lack access to it
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles